Action to be Taken at the Closing. The sale, conveyance, assignment and delivery of the Purchased Assets and the payment of the Purchase Price pursuant to the terms of this Agreement shall take place at the Closing, and, simultaneously, the other transactions contemplated by this Agreement shall take place by the delivery of all of the closing documents set forth in Section 7.3.
Action to be Taken at and after Closing.
Action to be Taken. If at any time during the period of three months after the date hereof, by reference to the facts and circumstances then existing, prior to the last of the dates on which the Warranties are deemed to be repeated pursuant to the provisions of clause 10.4, any matter or event comes to the attention of the Company or any of the Hong Kong Underwriters as a result of which any of the Warranties, if repeated immediately after the occurrence of such matter or event, would be untrue, inaccurate or misleading or which would or might render untrue, inaccurate or misleading any statement, whether of fact or opinion, contained in any of the Hong Kong Offering Documents or the Formal Notice if the same were issued immediately after the occurrence of such matter or event, the Company or such Hong Kong Underwriter (as the case may be) shall forthwith notify each of the other parties hereto and, without prejudice to any other rights of any party, the Company and the Sponsors on behalf of the Hong Kong Underwriters shall forthwith consult with a view to agreeing, if the Hong Kong Prospectus has already been registered with the Registrar of Companies in Hong Kong or distributed (as the case may be), what announcement or circular or document, if any, should be issued, published, distributed or made available or what other act or thing should be done. The Company agrees not to issue, publish, distribute or make publicly available any such announcement, circular or document without the prior written consent of the Sponsors (for themselves and on behalf of the Hong Kong Underwriters).
Action to be Taken. If you discover a fire anywhere: • Break the glass of the nearest alarm box before you do anything else • If possible, dial 999 for the Fire Brigade and ask them to attend Xxxxxx Xxxxxxx Xxxxxx, 00 Xxxxxxx Xxxx XX0 0XX • Ensure your own route of escape. • Advise your point of contact for the event
Action to be Taken. WBC <4.0X10 9/1 withhold until discussed with rheumatology team Neutrophils <2x109/1 withhold until discussed with rheumatology team Platelets <150x109/1 withhold until discussed with rheumatology team >2-fold rise in AST, ALT (from upper limit of reference range) withhold until discussed with rheumatology team Unexplained fall in albumin withhold until discussed with rheumatology team Rash or oral ulceration withhold until discussed with rheumatology team New or increasing dyspnoea or cough withhold until discussed with rheumatology team MCV>105fl Investigate and if B12 or folate low start appropriate supplementation Significant deterioration in renal function Reduce dose Abnormal bruising or sore throat Withhold until FBC result available Please note that in addition to absolute values for haematological indices a rapid fall or a consistent downward trend in any value should prompt caution and extra vigilance. SUPPORTING INFORMATION The National Patient Safety Agency has published actions to reduce the risks associated with oral methotrexate (see website). Side Effects Low-dose methotrexate may be associated with a number of serious adverse effects, including: hepatotoxicity pulmonary toxicity bone-marrow toxicity Other common non-life-threatening adverse effects of low-dose methotrexate are those affecting the gastrointestinal system (nausea, diarrhoea and stomatitis), and the central nervous system (headaches, drowsiness, blurred vision). The risk of minor adverse effects may be reduced by giving regular folic acid. An annual influenza vaccination is recommended. Guidance for Women of child-bearing age Methotrexate is teratogenic and female patients of child-bearing age should be prescribed or offered contraception. If patients wishes to start a family, it is advised that they stop the methotrexate for 3 to 6 months before conception. Drug interactions Methotrexate is extensively protein-bound and may be displaced by other protein-bound drugs (e.g. diuretics, salicylates, hypoglycaemics), with a potential for increased toxicity. Concomitant use of other drugs with nephrotoxic or hepatotoxic potential (including alcohol) should be avoided. Folate antagonists such as trimethoprim should not be given concomitantly. The British Society for Rheumatology Guidelines state that NSAIDs are not contraindicated with the above doses of methotrexate. References Prescribing and monitoring of Disease. DMARDs for inflammatory arthritis. Arthritis Research Counci...
Action to be Taken. 1. Employees who test negative shall be returned to regular duty their next regularly scheduled shift.
Action to be Taken a. When a set is determined to be a special problem set, Xxxxx XX (III) 6 of the AIDCP will apply to the future DMLs of the vessel involved, in accordance with the following schedule:
Action to be Taken. In summary of the above, please do the following as soon as possible: First: Read carefully the Prospectus and the terms of this Stock Award Agreement, and determine whether you would like to accept the Stock Award. If you choose to accept the Stock Award, you must sign and return this Agreement by no later than _______________, 2005. Next: Decide whether you will hold the Company Stock, sell it through a broker of your own choice, or sell it through the Custodial Sale Process. If you decide to hold the Company Stock or sell it through a broker of your own choice, you must pay to the Company an amount equal to your withholding taxes on the Stock Award, within five business days of the grant date. If you choose to sell your Company Stock through the Custodial Sales Process, you must return a signed Custodial Sale Agreement to the Company at the same time that you return the signed Stock Award agreement. If you have any questions, please contact ____________________ at ________________. XXXXXXXX TECHNOLOGIES, INC. _________________________________ By: [Insert name] I hereby accept the terms of this Stock Award Agreement and the Stock Award to be granted to me. _________________________________ By: [Insert name] OR I do not want the Stock Award described in this Agreement. I understand that by rejecting the Stock Award, I will not be entitled to any form of compensation in lieu thereof. _________________________________
Action to be Taken. At Closing Subject to the provisions of this Agreement, and in reliance upon the mutual representations, warranties, agreements and undertakings of Seller and Purchaser; the following shall take place at Closing:
Action to be Taken. The Commission may wish to:
